BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2025 10:16:46 AM | Browse: 184 | Download: 1081
 |
Received |
|
2025-01-08 04:58 |
|
Peer-Review Started |
|
2025-01-08 04:58 |
|
First Decision by Editorial Office Director |
|
2025-02-14 08:46 |
|
Return for Revision |
|
2025-02-14 08:46 |
|
Revised |
|
2025-02-17 11:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-03-03 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-04 12:39 |
|
Articles in Press |
|
2025-03-04 12:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-13 08:11 |
|
Publish the Manuscript Online |
|
2025-03-26 10:16 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Pinaki Chakraborty and Mrinal Borgohain |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mrinal Borgohain, MD, Medical Affairs, MSN Laboratories, H. No. 2-91/10 & 11/MSN, Whitefields, Kondapur, Hyderabad 500084, Telangāna, India. mrinal.borgohain@msnlabs.com |
| Key Words |
Pregabalin; Cancer; Neuropathic pain; Depression |
| Core Tip |
The study found that pregabalin significantly reduced both pain intensity and depression severity in terminal cancer patients. Pain levels, as measured by the brief pain inventory, saw a 47.4% reduction, while depressive symptoms, assessed using the Hamilton depression rating scale, experienced a similar reduction of 47.0%. Side effects were manageable, with no severe adverse effects reported. These findings indicate that pregabalin holds promise as a treatment option to improve the quality of life in terminal cancer patients, though further research is needed to substantiate these results. |
| Publish Date |
2025-03-26 10:16 |
| Citation |
Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
|
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i4.104827 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
